Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 3/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.53 |
| ▸ | SRC | P12931 | 7/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518287 | 0.74 | JAK2 (0.44) | PRKCQPRKCD | |
| SCHEMBL1939129 | 0.73 | AKT1 (0.64) | TNIKCHKA | |
| SCHEMBL148919 | 0.72 | KCNJ1 (0.61) | CHKAHRH3 | |
| SCHEMBL5520897 | 0.69 | CHKA (0.48) | PRKCQPRKCDSRCTNIKABL1 | |
| SCHEMBL28805850 | 0.68 | CHEK1 (0.45) | SRCABL1ABL2CHKACHEK1 | |
| SCHEMBL29809149 | 0.67 | HRH3 (0.60) | TNIKCHKAHRH3 | |
| SCHEMBL1482500 | 0.67 | HRH3 (0.60) | TNIKCHKAHRH3 | |
| SCHEMBL21633114 | 0.67 | KCNJ1 (0.54) | CHKAHRH3 | |
| SCHEMBL151521 | 0.67 | CHKA (0.69) | CHKAHRH3 | |
| SCHEMBL4946592 | 0.67 | SRC (0.64) | PRKCQPRKCDSRCABL1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | PRKCQ 286/4885PRKCD 356/4885SRC 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.